Search

Annamycin

Edivoxetine

Edivoxetine failed to be approved for major depressive disorder after phase III clinical trials in 2012. … Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant

Telavancin

MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others.

Sitimagene ceradenovec

Sitimagene ceradenovec is a novel gene-based product for the treatment of patients with operable high grade glioma, a type of malignant brain tumour, given in addition to standard surgery and radiotherapy

AZD0947

As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline.

Temanogrel

APD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena.

BB 21217

BB 21217 is an anti-BCMA CAR T cell therapy that uses the same CAR molecule as [idecabtagene vicleucel] (bb2121), but adds the PI3K inhibitor bb007 during ex vivo culture to enrich the drug product (DP

Viralym-C

It was granted FDA orphan designation in January 2017 and investigated for the treatment of CMV infection.[A260291, L47241] … Viralym-C is an investigational T-cell immunotherapy developed by ViraCyte. It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes.

Gabexate

Gabexate has been investigated for use in cancer, ischemia-reperfusion injury, and pancreatitis.[A19218,A19219,A19220] … Gabexate is a synthetic serine protease inhibitor which has been used as an anticoagulant. It also known to decrease production of inflammatory cytokines.

Oxidronic acid